CoxyPet-227
Firocoxib Chewable Tablets
CoxyPet-227
Tablets
Coxypet contains the active substance firocoxib 227mg, which belongs to a class of medicines having anti-inflammatory action.
Composition:
Each chewable tablet contains-
Firocoxib...........................................................227mg
Excipient............................................................q.s
Colour- Approved Colour used
Description:
Coxypet is used to treat pain and inflammation caused on by osteoarthritis, soft-tissue, orthopaedic, and dental surgery in dogs, as well as to treat osteoarthritis-related pain and inflammation in horses and to minimize associated lameness. The weight, type of animal, and condition to be treated will determine the dose, length of treatment, and frequency.
Indications:
* For the relief of post-operative pain and inflammation associated with soft-tissue, orthopaedic and dental surgery in dogs.
*For the relief of pain and inflammation associated with osteoarthritis in dogs.
Dosage & Administration:
As recommended by your veterinarian, take 5 mg per kg bodyweight once daily. Coxypet (firocoxib) is advised for oral administration in dogs at a dose of (5.0mg/kg) body weight once daily as needed for osteoarthritis and for three days as needed for postoperative pain and inflammation associated with soft-tissue and orthopaedic surgery. Coxypet can be given to the dogs around two hours before surgery. Coxypet Chewable Tablets are safe to take with or without meals.
Precautions:
Use in very young animals, or animals with
: suspected or confirmed impairment of renal, cardiac or hepatic function may involve additional risk. If such use cannot be avoided, those dogs require careful veterinary monitoring.
Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided.
Use this product under strict veterinary monitoring where there is a risk of gastrointestinal bleeding, or if the animal previously displayed intolerance to NSAIDs.
Renal and/or hepatic disorders have been reported in very rare cases in dogs administered the recommended treatment dose.
The treatment should be discontinued if any of these signs are observed: repeated diarrhea, vomiting, faecal occult blood, sudden weight loss, anorexia, lethargy, degradation of renal or hepatic biochemistry parameters
Contraindications:
Do not use in pregnant or lactating bitches.
Do not use in animals less than 10 weeks of age or less than 3 kg body weight.
Do not use in animals suffering from gastrointestinal bleeding, blood dyscrasia or haemorrhagic disorders.
Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs).
Warning:
Not for use in humans, Keep this out of the reach of children, Consult a physician in case of accidental ingestion by humans.
For oral use in dogs. Use of this product at doses above the recommended 5.0 mg/kg in puppies less than seven months of age has been associated with serious adverse reactions. Due to tablet sizes and scoring, dogs weighing less than 5.7kg cannot be rately dosed.
Pharmacology Pharmacokinetics: The absolute bioavailability of Coxypet
(firocoxib) is approximately 38% when administered as a 5 mg/kg oral dose to fasted adult dogs. Firocoxib is rapidly cleared from the blood via hepatic metabolism and fecal excretion (CLsystemic = ~0.4 L/hr/kg). Despite a high level of plasma protein binding (96%), firocoxib exhibits a large volume of distribution (Vd of total drug = ~4.6 L/kg) and a terminal elimination half life of 7.8 hours (%CV = 30%). The oral drug absorption process is highly variable among subjects. Co-administration of Coxypet with food delays drug absorption (Tmax from 1 to 5 hours) and decreases peak concentrations (Cmax from 1.3 to 0.9 mcg/mL). However, food does not affect the overall oral bioavailability at the recommended dose.
Adverse reactions
Emesis and diarrhea have occasionally been reported. These reactions are generally of a transitory nature and are reversible when the treatment is stopped. Renal and/or hepatic disorders have been reported in very rare cases in dogs administered the recommended treatment dose. Rarely, nervous system disorders have been reported in treated dogs. If adverse reactions like vomiting, repeated diarrhea, fecal occult blood, sudden weight loss, anorexia, lethargy, degradation of renal or hepatic biochemistry parameters occur, use of the product should be stopped and the advice of a veterinarian should be sought. As with other NSAIDs, serious adverse effects can occur and, in very rare cases, may be fatal.
Presentation:
10x1x6 Chewable Tablets
Storage:
Store in a dry place at a temperature not exceeding 30°C. Protect from light.
KEEP OUT OF THE REACH OF THE CHILDREN
NOT FOR HUMAN USE
FOR ANIMAL TREATMENT ONLY
Manufactured By Manufactured in India by: Safecon Lifesciences Pvt. Ltd. B-36 E.P.I.P. Shastri Puram, UPSIDC, Sikandra-282007
Marketed By
Medilogy Biotech
An ISO 9001: 2008 Certified Co.
24, Industrial Area, Ambala Cantt - 133001 SPO: Kazi Sayed Street, Mumbai - 400 009
Customer care: medilogybiotech@gmail.com
